It is estimated that in 2025 there will be a total of 226,650 new cases of lung and bronchus cancer in the United States. The highest number of these cases are estimated to be in the state of Florida. This statistic presents the estimated number of new lung and bronchus cancer cases in the United States in 2025, by state.

From 2018 to 2022, the overall death rate for lung and bronchus cancer in the Kentucky was 61 per 100,000 for males and 43.2 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by state and gender.

Information about the rates of cancer deaths in each state is reported. The data shows the total rate as well as rates based on sex, age, and race. Rates are also shown for three specific kinds of cancer: breast cancer, colorectal cancer, and lung cancer.

Original Data

Column Description

Summary statistics of lung cancer incidence rates for Blacks and Whites in 8 U.S. Geographic Regions, 1999–2012 (cases per 100,000).

This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

This statistic shows the death rate of lung and bronchus cancer in the United States from 1999 to 2023. The maximum rate in the given period was **** per every 100,000 age-adjusted population in 2000. The minimum rate stood at **** in 2023.

Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Lung cancer is a leading cause of cancer-related death in the US. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. Most cases are due to long-term tobacco smoking or exposure to secondhand tobacco smoke. Cities and communities can take an active role in curbing tobacco use and reducing lung cancer by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

https://www.cancerimagingarchive.net/wp-content/uploads/nctn-logo-300x108.png" alt="" width="300" height="108" />

Demographic Summary of Available Imaging

Characteristic	Value (N = 26254)
Age (years)	Mean ± SD: 61.4± 5 Median (IQR): 60 (57-65) Range: 43-75
Sex	Male: 15512 (59%) Female: 10742 (41%)
Race	White: 23969 (91.3%) Black: 1135 (4.3%) Asian: 547 (2.1%) American Indian/Alaska Native: 88 (0.3%) Native Hawaiian/Other Pacific Islander: 87 (0.3%) Unknown: 428 (1.6%)
Ethnicity	Not Available

Background: The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer.

Methods: From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. This dataset includes the low-dose CT scans from 26,254 of these subjects, as well as digitized histopathology images from 451 subjects.

Results: The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02).

Conclusions: Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385).

Data Availability: A summary of the National Lung Screening Trial and its available datasets are provided on the Cancer Data Access System (CDAS). CDAS is maintained by Information Management System (IMS), contracted by the National Cancer Institute (NCI) as keepers and statistical analyzers of the NLST trial data. The full clinical data set from NLST is available through CDAS. Users of TCIA can download without restriction a publicly distributable subset of that clinical data, along with the CT and Histopathology images collected during the trial. (These previously were restricted.)

Summary statistics of average lung cancer incidence rates and average daily smokers in percentage in 8 U.S. geographic regions, 1999–2012.

It is estimated that in 2025 there will be a total of ******* new cases of lung and bronchus cancer in the United States. In addition, it is predicted that there will be around ******* deaths from lung and bronchus cancer that year. This statistic presents the estimated number of new lung and bronchus cancer cases and deaths in the United States in 2025, by gender.

Financial overview and grant giving statistics of Lung Cancer Foundation of America

Summary statistics of lung cancer incidence rates for Whites in 8 U.S. geographic regions, 1999–2012 (cases per 100,000).

Summary statistics for lung cancer incidence rates for Blacks and Whites in the Mid-South by gender, 1999–2012 (cases per 100,000).

Population based cancer incidence rates were abstracted from National Cancer Institute, State Cancer Profiles for all available counties in the United States for which data were available. This is a national county-level database of cancer data that are collected by state public health surveillance systems. All-site cancer is defined as any type of cancer that is captured in the state registry data, though non-melanoma skin cancer is not included. All-site age-adjusted cancer incidence rates were abstracted separately for males and females. County-level annual age-adjusted all-site cancer incidence rates for years 2006–2010 were available for 2687 of 3142 (85.5%) counties in the U.S. Counties for which there are fewer than 16 reported cases in a specific area-sex-race category are suppressed to ensure confidentiality and stability of rate estimates; this accounted for 14 counties in our study. Two states, Kansas and Virginia, do not provide data because of state legislation and regulations which prohibit the release of county level data to outside entities. Data from Michigan does not include cases diagnosed in other states because data exchange agreements prohibit the release of data to third parties. Finally, state data is not available for three states, Minnesota, Ohio, and Washington. The age-adjusted average annual incidence rate for all counties was 453.7 per 100,000 persons. We selected 2006–2010 as it is subsequent in time to the EQI exposure data which was constructed to represent the years 2000–2005. We also gathered data for the three leading causes of cancer for males (lung, prostate, and colorectal) and females (lung, breast, and colorectal). The EQI was used as an exposure metric as an indicator of cumulative environmental exposures at the county-level representing the period 2000 to 2005. A complete description of the datasets used in the EQI are provided in Lobdell et al. and methods used for index construction are described by Messer et al. The EQI was developed for the period 2000– 2005 because it was the time period for which the most recent data were available when index construction was initiated. The EQI includes variables representing each of the environmental domains. The air domain includes 87 variables representing criteria and hazardous air pollutants. The water domain includes 80 variables representing overall water quality, general water contamination, recreational water quality, drinking water quality, atmospheric deposition, drought, and chemical contamination. The land domain includes 26 variables representing agriculture, pesticides, contaminants, facilities, and radon. The built domain includes 14 variables representing roads, highway/road safety, public transit behavior, business environment, and subsidized housing environment. The sociodemographic environment includes 12 variables representing socioeconomics and crime. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., L. Messer, K. Rappazzo , C. Gray, S. Grabich , and D. Lobdell. County-level environmental quality and associations with cancer incidence#. Cancer. John Wiley & Sons Incorporated, New York, NY, USA, 123(15): 2901-2908, (2017).

Lung Cancer Diagnostic Tests Market Outlook

The lung cancer diagnostic tests market size was valued at USD 2.5 billion in 2023 and is projected to reach USD 6.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. This substantial growth can be attributed to the rising prevalence of lung cancer globally, advancements in diagnostic technologies, and increasing awareness regarding early detection and treatment of lung cancer. The growing aging population and the high incidence of smoking, which is a leading cause of lung cancer, further propel the demand for diagnostic tests.

The increasing prevalence of lung cancer is one of the primary drivers of market growth. Lung cancer remains the leading cause of cancer-related deaths worldwide, necessitating the development of more accurate and early diagnostic methods. With advancements in medical technology, such as molecular diagnostics and non-invasive imaging techniques, the accuracy and efficiency of lung cancer diagnosis have significantly improved. These innovations not only enhance the detection rate but also facilitate personalized treatment plans, thereby improving patient outcomes.

Furthermore, government initiatives and funding for cancer research play a crucial role in market expansion. Many countries are investing heavily in cancer research, leading to the development of new diagnostic tools and techniques. For instance, organizations such as the National Cancer Institute (NCI) in the United States provide substantial grants for lung cancer research, fostering innovations in diagnostics. In addition, public awareness campaigns and screening programs conducted by healthcare organizations and governments encourage early diagnosis, which is vital for successful treatment and survival rates.

The integration of artificial intelligence (AI) and machine learning in diagnostic tools is another significant factor contributing to market growth. AI algorithms can analyze medical images with high precision, aiding radiologists in identifying lung cancer at earlier stages. Moreover, AI-driven software can evaluate large datasets from genetic and molecular tests, providing insights into the most effective treatment options based on individual patient profiles. This technological advancement not only enhances the accuracy of diagnostics but also reduces the time required for analysis, thereby increasing the efficiency of healthcare services.

The EGFR Mutation Test is a pivotal advancement in the realm of lung cancer diagnostics, offering a more personalized approach to treatment. This test specifically identifies mutations in the Epidermal Growth Factor Receptor (EGFR) gene, which are often present in non-small cell lung cancer (NSCLC) patients. By detecting these mutations, healthcare providers can tailor therapies that target the specific genetic alterations, thereby improving treatment efficacy and patient outcomes. The growing adoption of EGFR Mutation Tests underscores the shift towards precision medicine, where treatments are increasingly customized based on individual genetic profiles. This approach not only enhances the effectiveness of therapies but also minimizes adverse effects, as treatments are more accurately aligned with the patient's unique genetic makeup.

Regionally, North America holds the largest share of the lung cancer diagnostic tests market, followed by Europe and Asia Pacific. The dominance of North America can be attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a robust research landscape. The Asia Pacific region, however, is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, growing awareness about lung cancer, and rising incidences of the disease in countries like China and India. The growing middle-class population and improving healthcare access in these countries further support market growth.

Test Type Analysis

The lung cancer diagnostic tests market is segmented by test type into imaging tests, sputum cytology, tissue biopsy, molecular tests, and others. Imaging tests are one of the most commonly used diagnostic methods for lung cancer detection. Techniques such as X-rays, CT scans, and PET scans provide detailed visuals of the lungs, helping in identifying abnormal growths or tumors. The non-invasive nature of these tests and their ability to provide quick results make them a preferred choice among healthcare

United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data was reported at 13.300 Ratio in 2016. United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data is updated yearly, averaging 13.300 Ratio from Dec 2016 (Median) to 2016, with 1 observations. United States US: Mortality Rate Attributed to Household and Ambient Air Pollution: per 100,000 Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Mortality rate attributed to household and ambient air pollution is the number of deaths attributable to the joint effects of household and ambient air pollution in a year per 100,000 population. The rates are age-standardized. Following diseases are taken into account: acute respiratory infections (estimated for all ages); cerebrovascular diseases in adults (estimated above 25 years); ischaemic heart diseases in adults (estimated above 25 years); chronic obstructive pulmonary disease in adults (estimated above 25 years); and lung cancer in adults (estimated above 25 years).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Snapshot img

Non-Small Cell Lung Cancer Drugs Market Size 2024-2028

The non-small cell lung cancer (NSCLC)drugs market size is forecast to increase by USD 21.06 billion at a CAGR of 10.87% between 2023 and 2028.

The non-small cell lung cancer (NSCLC) drug market is experiencing significant growth due to several factors. The increasing prevalence of NSCLC, driven by air pollution and smoking behaviors, is a major market driver. Additionally, the approval and introduction of combination therapies, such as those involving HER2-positive gastric and gastroesophageal (GEJ) adenocarcinoma medications, are contributing to market expansion.
However, the high cost of NSCLC treatment poses a challenge to market growth. Daiichi Sankyo and other pharmaceutical companies are focusing on developing new treatments, including Fruquintinib (HMPL-013) and PD-L1 antibody therapies, to address this need and meet the demands of the growing patient population.

What will be the Non-Small Cell Lung Cancer Drugs Market Size During the Forecast Period?

Request Free Sample

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The NSCLC drugs market encompasses various treatment modalities, including small molecules, biologics, alkylating agents, antimetabolites, mitotic inhibitors, multi-kinase inhibitors, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The NSCLC drugs market has seen significant advancements in recent years, driven by the development of innovative treatment options. Small molecules and biologics have been the primary focus of research and development (R&D) efforts due to their targeted approach and improved efficacy. The pipeline for NSCLC drugs is strong, with several promising candidates in various stages of clinical development. One such candidate is Fruquintinib (HMPL-013), a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, which is currently under investigation for the treatment of advanced NSCLC. Another promising development is the use of PD-L1 antibodies in immunotherapy, which has shown promising results in clinical trials.
The diagnosis and treatment of NSCLC involve various modalities, including CT scans and radiation therapy. Radiation oncologists play a crucial role in the management of NSCLC patients, using advanced technologies such as deep learning systems to optimize radiation therapy plans. The risk factors for NSCLC include a history of smoking, exposure to air pollution, and occupational hazards such as asbestos and arsenic. The availability and accessibility of these drugs depend on various factors, including insurance coverage, geographic location, and patient demographics. The NSCLC drugs market is expected to continue growing due to the increasing prevalence of the disease and the development of new and innovative treatment options. The use of advanced technologies such as deep learning systems and targeted therapies is expected to drive the growth of the market in the coming years.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Adenocarcinoma
  Squamous cell carcinoma
  Large cell carcinoma


Product

  Biologics
  Small molecule targeted therapy
  Chemotherapy


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The adenocarcinoma segment is estimated to witness significant growth during the forecast period.

Adenocarcinoma is a type of cancer that develops in the glandular tissue, which produces and secretes substances into the body. This form of cancer affects various organs, including the breast, lungs, esophagus, stomach, colon, rectum, pancreas, prostate, and uterus. Several factors contribute to the development of adenocarcinoma. Smoking is a significant risk factor for adenocarcinoma, making it a leading cause of this disease. Exposure to toxins in the home or work environment can also contribute to its development. Previous radiation therapy is another risk factor, increasing the likelihood of adenocarcinoma. In Massachusetts, researchers are developing innovative solutions to combat adenocarcinoma.

For instance, a deep learning system has been designed to analyze CT scans and assist radiation oncologists in diagnosing and treating the disease more accurately. Additionally, companies like Moderna and Rain Therapeutics are exploring the use of messenger RNA (mRNA) and anti-TIM-3 antibody, respectively, for targeted therapy. These advancements in technology and pharmaceuticals offer hope for improving life expectancy for patients diagnosed with adenocarcinoma. By c

Lung cancer incidence rates by race, 1999–2012 (cases per 100,000).

BackgroundBetter information on lung cancer occurrence in lifelong nonsmokers is needed to understand gender and racial disparities and to examine how factors other than active smoking influence risk in different time periods and geographic regions. Methods and FindingsWe pooled information on lung cancer incidence and/or death rates among self-reported never-smokers from 13 large cohort studies, representing over 630,000 and 1.8 million persons for incidence and mortality, respectively. We also abstracted population-based data for women from 22 cancer registries and ten countries in time periods and geographic regions where few women smoked. Our main findings were: (1) Men had higher death rates from lung cancer than women in all age and racial groups studied; (2) male and female incidence rates were similar when standardized across all ages 40+ y, albeit with some variation by age; (3) African Americans and Asians living in Korea and Japan (but not in the US) had higher death rates from lung cancer than individuals of European descent; (4) no temporal trends were seen when comparing incidence and death rates among US women age 40–69 y during the 1930s to contemporary populations where few women smoke, or in temporal comparisons of never-smokers in two large American Cancer Society cohorts from 1959 to 2004; and (5) lung cancer incidence rates were higher and more variable among women in East Asia than in other geographic areas with low female smoking. ConclusionsThese comprehensive analyses support claims that the death rate from lung cancer among never-smokers is higher in men than in women, and in African Americans and Asians residing in Asia than in individuals of European descent, but contradict assertions that risk is increasing or that women have a higher incidence rate than men. Further research is needed on the high and variable lung cancer rates among women in Pacific Rim countries.